Cisplatin-induced peripheral neuropathy: Neuroprotection by erythropoietin without affecting tumour growth

Roberto Bianchi, Alessandra Gilardini, Virginia Rodriguez-Menendez, Norberto Oggioni, Annalisa Canta, Tina Colombo, Giulia De Michele, Sara Martone, Alessandra Sfacteria, Giuseppe Piedemonte, Giovanni Grasso, Patrizia Beccaglia, Pietro Ghezzi, Maurizio D'Incalci, Giuseppe Lauria, Guido Cavaletti

Research output: Contribution to journalArticlepeer-review


This study examined the dose-dependent efficacy of erythropoietin (EPO) for preventing and/or treating cisplatin (CDDP) induced peripheral neurotoxicity (CINP), and its influence on tumour treatment and growth. Rats received eight intraperitoneal (ip) injections of 2 mg/kg CDDP twice weekly. EPO co-administered (50 or 10 μg/kg ip, three times/week) had a dose-dependent effect, partially preventing CINP, but 0.5 μg/kg ip was not effective. The neuroprotective effect lasted at least 5 weeks after the last dose of EPO and CDDP. In addition, EPO (50 μg/kg ip three times/week) after the last injection of CDDP still induced a significant recovery of CINP. In a separate experiment in rats bearing mammary carcinoma EPO treatment (50 μg/kg ip) given concurrently with CDDP (1.0 and 1.5 mg/kg twice a week for four weeks) was neuroprotective without influencing the effectiveness of the treatment or tumour growth. EPO thus appears to be an effective neuroprotectant that does not interfere with tumour treatment.

Original languageEnglish
Pages (from-to)710-717
Number of pages8
JournalEuropean Journal of Cancer
Issue number4
Publication statusPublished - Mar 2007


  • Cisplatin
  • Erythropoietin
  • Neurophysiology
  • Pathology
  • Peripheral neuropathy
  • Rat
  • Tumour growth

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology


Dive into the research topics of 'Cisplatin-induced peripheral neuropathy: Neuroprotection by erythropoietin without affecting tumour growth'. Together they form a unique fingerprint.

Cite this